The Pfizer Clinical Research Unit in New Haven is conducting a clinical trial of a study drug for atopic dermatitis (AD; eczema) and asthma. This part of the study will look at the effects of daily doses of the study drug when given to adults with mild-to-moderate asthma. You do not need to discontinue your current asthma treatment to participate in this study.
This study is looking at a potential treatment for AD and asthma, which are both inflammatory conditions - diseases in which excess or ongoing inflammation is a primary factor.
AD is one of the most common chronic inflammatory skin conditions. It causes a rash, itching, and can negatively affect patients’ emotional well-being. Asthma is a long-term respiratory condition caused by inflammation in the lungs and airways. This leads to symptoms such as shortness of breath, difficulty breathing, chest tightness, coughing, and wheezing.
Patients with these conditions often still face symptoms despite current treatments and may benefit from other medication options.
Learn how you can get involved below.
Who may participate
Participants in clinical trials are essential to making advancements in medicine, and we appreciate your interest in joining one of our trials.
This study is seeking adults diagnosed with mild-to-moderate asthma. In addition to the criteria listed, participants must be:
- Willing to take a study drug
- Willing and able to come to our facility in New Haven, CT*
- Willing and able to comply with all study procedures
*participants may be eligible to receive a bonus for travel, ask our staff for details
**female participants must be unable to bear children
There are other requirements for participation in this study. The study staff will explain these to you during the screening process.
Do you know someone who may meet these requirements? Refer a friend and you may be eligible to receive a bonus.
Condition
Mild-to-Moderate Asthma
Age
18-65 years
Sex
All sexes**
Referral bonus
Up to $300
Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.
What to expect
If this study may be a fit for you, you’ll be invited to complete up to two screening visits at our facility in New Haven, CT. If you qualify for the study, there may be a period of up to 56 days before dosing.
If you choose to participate, you will stay at our facility for 18 overnights in a row. Starting the second morning after you arrive, you will receive a single dose of the study drug or a placebo (no active ingredient) once a day for 2 weeks, up to a total of 14 doses. Whether you receive the study drug or placebo will be chosen at random. All doses will be given as tablets or a liquid to swallow and may be given with or without food.
Throughout the study, staff will closely monitor your health status and collect data, such as the levels of the study drug in your blood.
This study requires you to stay at the PCRU for the entire duration of each inpatient stay unless you choose to withdraw. You can learn more about what to expect during your participation by browsing our FAQ section.
Required overnight stays
18 consecutive overnights
Long-term follow up
1 phone call
How long is this study?
About 44 days
Compensation
$175 per screening visit; Up to $8,200 upon completion of the study
All of the study procedures will be clearly explained to you during screening and can be viewed in the informed consent form.
We've updated the PCRU Loyalty Program!
We refreshed our Participant Loyalty Program with all-new unique tiered gifts for new and returning participants.
Get started — See if you may be eligible
Complete this 3-minute questionnaire about your health and medical history to see if this study might be a good fit for you. You may also call 1-800-254-6398 and speak with a PCRU representative to complete the prescreening or learn more about the study.
If you choose to submit your responses, a representative will contact you within 2-3 days to complete the process and discuss next steps.
The personal data gathered here will be collected, processed, and maintained in a confidential manner. If you are not eligible or choose not to submit your responses, your individual data will not be linked to you directly but may be shared in anonymous reports of aggregate data. This prescreener is not a full assessment of eligibility. Only the study staff can determine if you are eligible to enroll in the study.